AU2019327430B2 - Combination therapy using C-C chemokine receptor 4 (CCR4) antagonists and one or more immune checkpoint inhibitors - Google Patents

Combination therapy using C-C chemokine receptor 4 (CCR4) antagonists and one or more immune checkpoint inhibitors Download PDF

Info

Publication number
AU2019327430B2
AU2019327430B2 AU2019327430A AU2019327430A AU2019327430B2 AU 2019327430 B2 AU2019327430 B2 AU 2019327430B2 AU 2019327430 A AU2019327430 A AU 2019327430A AU 2019327430 A AU2019327430 A AU 2019327430A AU 2019327430 B2 AU2019327430 B2 AU 2019327430B2
Authority
AU
Australia
Prior art keywords
alkyl
nrarb
alkylene
ccr4
ctla
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019327430A
Other languages
English (en)
Other versions
AU2019327430A1 (en
Inventor
Shijie Li
Venkat Reddy Mali
Rajinder Singh
Ju Yang
Penglie Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemocentryx Inc
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of AU2019327430A1 publication Critical patent/AU2019327430A1/en
Application granted granted Critical
Publication of AU2019327430B2 publication Critical patent/AU2019327430B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/82—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/852—Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2019327430A 2018-08-29 2019-08-28 Combination therapy using C-C chemokine receptor 4 (CCR4) antagonists and one or more immune checkpoint inhibitors Active AU2019327430B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862724412P 2018-08-29 2018-08-29
US62/724,412 2018-08-29
US201862771853P 2018-11-27 2018-11-27
US62/771,853 2018-11-27
PCT/US2019/048461 WO2020047030A1 (en) 2018-08-29 2019-08-28 Combination therapy using c-c chemokine receptor 4 (ccr4) antagonists and one or more immune checkpoint inhibitors

Publications (2)

Publication Number Publication Date
AU2019327430A1 AU2019327430A1 (en) 2021-03-18
AU2019327430B2 true AU2019327430B2 (en) 2024-10-03

Family

ID=69639506

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019327430A Active AU2019327430B2 (en) 2018-08-29 2019-08-28 Combination therapy using C-C chemokine receptor 4 (CCR4) antagonists and one or more immune checkpoint inhibitors

Country Status (16)

Country Link
US (2) US11446289B2 (enExample)
EP (1) EP3843734B1 (enExample)
JP (1) JP7554180B2 (enExample)
KR (1) KR102817790B1 (enExample)
CN (1) CN112601526B (enExample)
AU (1) AU2019327430B2 (enExample)
BR (1) BR112021002928A2 (enExample)
CA (1) CA3109498A1 (enExample)
ES (1) ES3064498T3 (enExample)
IL (1) IL280831B2 (enExample)
MA (1) MA53503A (enExample)
MX (1) MX2021002302A (enExample)
SG (1) SG11202101454PA (enExample)
TW (1) TWI888358B (enExample)
WO (1) WO2020047030A1 (enExample)
ZA (1) ZA202101055B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6141864B2 (ja) 2011-12-01 2017-06-07 ケモセントリックス，インコーポレイティド Ｃｃｒ（４）アンタゴニストとしての置換アニリン
ES3064498T3 (enExample) * 2018-08-29 2026-04-27 Chemocentryx Inc
KR20230149729A (ko) * 2022-04-19 2023-10-27 케모센트릭스, 인크. Ccr4 길항제

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US20020173524A1 (en) * 2000-10-11 2002-11-21 Tularik Inc. Modulation of CCR4 function
AU2003256923A1 (en) 2002-07-31 2004-02-16 Smithkline Beecham Corporation Substituted benzanilides as modulators of the ccr5 receptor
JP2007210887A (ja) 2004-06-21 2007-08-23 Astellas Pharma Inc 縮合二環性ピリミジン誘導体
US20090182140A1 (en) 2005-12-02 2009-07-16 Mitsubishi Tanabe Pharma Corporation Alicyclic Heterocyclic Compound
GB0718167D0 (en) 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target
JP2009148309A (ja) 2007-12-18 2009-07-09 Uni Charm Corp 吸収性物品
US8263073B2 (en) 2008-02-04 2012-09-11 Medarex, Inc. Anti-CTLA-4 antibodies with reduced blocking of binding of CTLA-4 to B7 and uses thereof
JP5523572B2 (ja) 2009-10-26 2014-06-18 中国石油化工股▲ふん▼有限公司 担持型非メタロセン触媒、その製造方法およびその使用
WO2011050565A1 (zh) 2009-10-26 2011-05-05 中国石油化工股份有限公司 负载型非茂金属催化剂、其制备方法及其应用
WO2011056423A2 (en) 2009-10-28 2011-05-12 Exxonmobil Chemical Patents Inc. Catalyst compounds and use thereof
US8952113B2 (en) 2009-11-13 2015-02-10 China Petroleum & Chemical Corp. Supported nonmetallocene catalyst, preparation and use thereof
EP2500364B1 (en) 2009-11-13 2020-03-04 China Petroleum & Chemical Corporation Supported non-metallocene catalyst preparation method and application thereof
US20140031547A1 (en) 2010-12-14 2014-01-30 Electrophoretics Limited CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES
JP6141864B2 (ja) * 2011-12-01 2017-06-07 ケモセントリックス，インコーポレイティド Ｃｃｒ（４）アンタゴニストとしての置換アニリン
CA2899577C (en) * 2013-04-03 2023-10-17 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
JP7305300B2 (ja) * 2014-11-05 2023-07-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 併用免疫療法
WO2016181349A1 (en) * 2015-05-14 2016-11-17 Pfizer Inc. Combinations comprising a pyrrolidine-2,5-dione ido1 inhibitor and an anti-body
TW201713332A (zh) * 2015-07-14 2017-04-16 協和醱酵麒麟有限公司 包含與抗體組合投予之ｉｄｏ抑制物之腫瘤治療劑
TWI724056B (zh) * 2015-11-19 2021-04-11 美商卡默森屈有限公司 Ｃｘｃｒ２抑制劑
SG10201603721TA (en) 2016-05-10 2017-12-28 Agency Science Tech & Res Anti-CTLA-4 Antibodies
KR102401963B1 (ko) 2016-06-27 2022-05-25 케모센트릭스, 인크. 면역조절제 화합물
PL3490565T3 (pl) * 2016-07-29 2022-09-26 Rapt Therapeutics, Inc. Pochodne azetydyny jako modulatory receptora chemokinowego i ich zastosowanie
WO2018035710A1 (en) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
WO2018101448A1 (en) * 2016-11-30 2018-06-07 Kyowa Hakko Kirin Co., Ltd. Method of treating cancer using anti-ccr4 antibody and anti-pd-1 antibody
ES3064498T3 (enExample) * 2018-08-29 2026-04-27 Chemocentryx Inc

Also Published As

Publication number Publication date
CA3109498A1 (en) 2020-03-05
ZA202101055B (en) 2025-08-27
NZ773164A (en) 2025-07-25
US12011439B2 (en) 2024-06-18
WO2020047030A1 (en) 2020-03-05
KR20210053306A (ko) 2021-05-11
EP3843734B1 (en) 2026-01-28
TWI888358B (zh) 2025-07-01
US20230097128A1 (en) 2023-03-30
TW202023555A (zh) 2020-07-01
MX2021002302A (es) 2021-04-28
IL280831B2 (en) 2024-05-01
JP2021536442A (ja) 2021-12-27
US11446289B2 (en) 2022-09-20
SG11202101454PA (en) 2021-03-30
MA53503A (fr) 2021-07-07
JP7554180B2 (ja) 2024-09-19
AU2019327430A1 (en) 2021-03-18
EP3843734C0 (en) 2026-01-28
EP3843734A1 (en) 2021-07-07
BR112021002928A2 (pt) 2021-05-11
IL280831B1 (en) 2024-01-01
CN112601526B (zh) 2025-10-03
EP3843734A4 (en) 2022-05-25
CN112601526A (zh) 2021-04-02
US20200069673A1 (en) 2020-03-05
ES3064498T3 (enExample) 2026-04-27
KR102817790B1 (ko) 2025-06-05
IL280831A (en) 2021-04-29

Similar Documents

Publication Publication Date Title
US11234977B2 (en) Fused tricyclic pyrazolo-dihydropyrazinyl-pyridone compounds as antivirals
AU2017219216B2 (en) Tetracyclic pyridone compounds as antivirals
US12011439B2 (en) Combination therapy using C—C chemokine receptor 4 (CCR4) antagonists and one or more immune checkpoint inhibitors
WO2019113071A1 (en) Compositions and methods for treating alk-mediated cancer
WO2019166951A1 (en) Indole-2-carbonyl compounds and their use for the treatment of hepatitis b
WO2020047035A1 (en) Methods of treating cancer with small molecule pd-l1 inhibitors
US20240115682A1 (en) Methods of treating cancer using heteroaryl-biphenyl amide derivatives
AU2019205784B2 (en) Methods of treating solid tumors with CCR2 antagonists
WO2025049964A1 (en) Bcl6 bifunctional degraders
EP4423075B1 (en) Ccr6 receptor modulators
RU2810717C2 (ru) Комбинированная терапия с использованием антагонистов c-c хемокинового рецептора 4 (ccr4) и одного или более ингибиторов контрольных точек
WO2025235814A1 (en) Potent asgpr-binding heterobifuctional compounds for the degradation of targeted extracellular proteins
WO2025094035A1 (en) Toll-like receptor agonists and conjugates thereof
TW202426441A (zh) 用於治療癌症之化合物

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)